Omeros Corporation (OMER)
OMER trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2020-12-31, https://www.sec.gov/Archives/edgar/data/1285819/000155837021002177/0001558370-21-002177-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2020-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | OMER on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2009 |
| SEC CIK | 0001285819 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | WA |
Financials · 2020
| Line | Value |
|---|---|
| Revenue | $73.8M |
| Net income | -$138.1M |
| Operating income | -$156.9M |
| Net margin | -187.0% |
| Operating margin | -212.6% |
| Revenue growth | -34.0% |
| Cash | $10.5M |
| Total assets | $181.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 16.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-12 |
| Cash and burn | $2.0M cash; operating cash flow -$17.2M a quarter. | Report 2026-06-30 |
| Shares outstanding | 72,388,316 (2026-08-07); 68,055,826 a year earlier; 62,855,824 three years earlier. | Cover page 2026-08-07 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Seattle, Washington, United States | PCAOB Form AP 2026-04-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $3.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $28.5M | $13.2M | $4.1M | $2.0M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $9.9M | $56.1M | -$14.5M | $1.9M | No debt tags | Needs four quarters | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | Not filed | $86.5M | -$39.8M | $9.7M | $87.9M | Needs four quarters | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | Not filed | -$30.9M | -$18.5M | $2.4M | $154.9M | Needs four quarters | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | $0 | -$25.4M | -$21.9M | $1.9M | $154.9M | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $0 | -$33.5M | -$35.8M | $4.3M | $164.9M | Needs four quarters | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | Not filed | -$31.4M | -$29.0M | $3.4M | $164.9M | Needs four quarters | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | Not filed | -$32.2M | -$32.1M | $1.5M | $164.9M | Needs four quarters | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-11-14 |
| Latest annual report FORM 10-K | 10-K | 2026-03-31 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-16 |
| Latest current report FORM 8-K | 8-K | 2026-11-16 |
| Latest proxy | DEF 14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 812 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.4% |
| 1 month | -7.4% |
| 3 months | +0.8% |
| Year to date | +1.8% |
| 1 year | +178.5% |
| From 52-week high | -16.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OPK | OPKO Health Inc. | $1.62 | -3.57% | $1.2B |
| KARD | Kardigan Inc. | $12.85 | -7.02% | $1.2B |
| SLN | Silence Therapeutics Plc American Depository Share | $19.80 | -0.15% | $1.2B |
| AAPG | Ascentage Pharma Group International American Depository Shares | $13.29 | -9.10% | $1.2B |
| CMPS | COMPASS Pathways Plc American Depository Shares | $8.27 | -8.21% | $1.2B |
| AMPH | Amphastar Pharmaceuticals Inc. | $29.17 | -0.68% | $1.2B |
| NKTR | Nektar Therapeutics | $36.44 | -2.23% | $1.2B |
| MNKD | MannKind Corporation | $3.96 | -4.24% | $1.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier